Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
August 20, 2012

CDD, SRI receive NIAID grant to develop tuberculosis drug discovery computational tools

The National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, has issued Phase II small business technology transfer research (STTR) grant to Collaborative Drug Discovery (CDD) and SRI International to advance the development of computational tools for tuberculosis drug discovery.

nih

The National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health, has issued a Phase II small business technology transfer research (STTR) grant to Collaborative Drug Discovery (CDD) and SRI International to advance the development of computational tools for tuberculosis drug discovery.

The STTR grant, which will support the next two years of research, will focus on extending a systems biology-cheminformatics approach to develop molecular mimics and computationally evaluate them for drug efficacy.

SRI International Information and Computer Science Division program director Dr Carolyn Talcott said; "After successful completion of Phase I, where we integrated intensive data mining, curation and computational approaches to suggest biological targets and their small molecule modulators, we now look forward to follow-up studies that will refine and validate our approach."

The companies will advance the research to further analyse the molecules discovered in Phase I and develop a software product for bioscience research.

The software is expected to provide query and analysis capabilities, and include links to other drug discovery tools and databases.

CDD science vice president Dr Sean Ekins said the project has already resulted in multiple publically accessible datasets, including experimental assays results and drug compounds information.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

"We will build upon the demonstrated proof-of-concept to identify more compounds active against tuberculosis to include in the repository," Ekins said.


Image: Aerial photograph from the north of the Mark O Hatfield Clinical Research Center (Building 10) on the National Institutes of Health Bethesda, Maryland campus. Photo: Courtesy of NIH.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU